NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News $823.71 +0.75 (+0.09%) (As of 11:15 AM ET) Add Compare Share Share Today's Range$817.14▼$833.2850-Day Range$727.13▼$844.3752-Week Range$668.00▼$847.50Volume94,554 shsAverage Volume582,649 shsMarket Capitalization$89.42 billionP/E Ratio21.77Dividend YieldN/APrice Target$900.92 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Regeneron Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside9.5% Upside$900.92 Price TargetShort InterestHealthy1.40% of Float Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment1.07Based on 21 Articles This WeekInsider TradingSelling Shares$27.23 M Sold Last QuarterProj. Earnings Growth2.60%From $35.42 to $36.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.30 out of 5 starsMedical Sector375th out of 969 stocksPharmaceutical Preparations Industry159th out of 454 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 20 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $900.92, Regeneron Pharmaceuticals has a forecasted upside of 9.5% from its current price of $822.96.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.40% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 2.03%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 3.4 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Regeneron Pharmaceuticals this week, compared to 11 articles on an average week.Search InterestOnly 4 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat Follows15 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 15% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,232,176.00 in company stock.Percentage Held by InsidersOnly 8.83% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions84.15% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 2.60% in the coming year, from $35.42 to $36.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 21.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 107.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 21.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.71.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.45. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Regeneron Pharmaceuticals (NASDAQ:REGN) StockRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesSeptember 25, 2023 | marketbeat.comAre Gene Therapy Stocks The Market's Next Big Winners? (REGN)Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.September 25, 2023 | marketbeat.comArgenx's 28% Surge & Promising Product Propel Investor Confidence (REGN)Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.October 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. October 1, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $680.00 at Bank of AmericaSeptember 30, 2023 | finance.yahoo.comStock Split Watch: Is Regeneron Pharmaceuticals Next?September 29, 2023 | markets.businessinsider.comRegeneron Pharma Reports FDA Priority Review For Odronextamab BLA - Quick FactsSeptember 29, 2023 | finance.yahoo.comOdronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority ReviewSeptember 28, 2023 | finance.yahoo.comRegeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023October 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 27, 2023 | finance.yahoo.comRegeneron Pharmaceuticals Stock Earns 85 RS RatingSeptember 26, 2023 | finance.yahoo.comDow Jones Futures Rise After Market Correction Worsens; Meta AI News DueSeptember 26, 2023 | finance.yahoo.comDupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority ReviewSeptember 26, 2023 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 25, 2023 | finance.yahoo.comUltragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)September 25, 2023 | msn.comRegeneron finalizes acquisition of Decibel Therapeutics, enhancing gene therapy portfolioSeptember 23, 2023 | finance.yahoo.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 40% Below Their Intrinsic Value EstimateSeptember 23, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Cantor FitzgeraldSeptember 22, 2023 | finance.yahoo.comTop Stock Reports for Amazon.com, Boeing, Regeneron & OthersSeptember 21, 2023 | markets.businessinsider.comAnalyst Expectations for Regeneron Pharmaceuticals's FutureSeptember 20, 2023 | msn.comRegeneron’s Eylea HD Gets FDA Approval, Boosting Company’s Growth OutlookSeptember 20, 2023 | finance.yahoo.comThis Recent FDA Approval Could Give Regeneron's Top Line a Big BoostSeptember 19, 2023 | seekingalpha.comRegeneron Pharmaceuticals: Game-Changing Discoveries In HealthcareSeptember 15, 2023 | msn.comArgus Research Maintains Regeneron Pharmaceuticals (REGN) Buy RecommendationSeptember 15, 2023 | msn.comWestPark Capital Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold RecommendationSeptember 11, 2023 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Management presents at Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)September 11, 2023 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)September 11, 2023 | forbes.comIs Regeneron Stock Fully Valued At $820?See More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Company Calendar Last Earnings8/03/2023Today10/02/2023Next Earnings (Confirmed)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees11,851Year Founded1988Price Target and Rating Average Stock Price Forecast$900.92 High Stock Price Forecast$1,050.00 Low Stock Price Forecast$680.00 Forecasted Upside/Downside+9.5%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage27 Analysts Profitability EPS (Most Recent Fiscal Year)$37.83 Trailing P/E Ratio21.75 Forward P/E Ratio23.23 P/E Growth2.45Net Income$4.34 billion Net Margins33.93% Pretax Margin37.69% Return on Equity19.19% Return on Assets14.94% Debt Debt-to-Equity Ratio0.11 Current Ratio5.45 Quick Ratio4.64 Sales & Book Value Annual Sales$12.67 billion Price / Sales7.05 Cash Flow$44.53 per share Price / Cash Flow18.48 Book Value$207.31 per share Price / Book3.97Miscellaneous Outstanding Shares108,559,000Free Float98,973,000Market Cap$89.34 billion OptionableOptionable Beta0.19 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 70)Ph.D., Co-Founder, Pres, CEO & Co-Chairman Comp: $7MDr. George D. Yancopoulos M.D. (Age 63)Ph.D., Co-Founder, Pres, Chief Scientific Officer & Co-Chairman Comp: $6.59MMr. Robert E. Landry Jr. (Age 59)Exec. VP of Fin. & CFO Comp: $1.84MDr. Andrew J. Murphy Ph.D. (Age 64)Exec. VP of Research Comp: $1.62MMr. Daniel P. Van Plew (Age 50)Exec. VP and GM of Industrial Operations & Product Supply Comp: $1.95MMs. Marion E. McCourt (Age 63)Exec. VP of Commercial Comp: $1.5MMs. Patrice GiloolySr. VP of Quality Assurance & OperationsMr. Christopher R. Fenimore CPA (Age 52)Sr. VP, Head of Accounting & Controller Mr. Gerald UnderwoodSr. VP of Technical OperationsMr. Bob McCowanSr. VP of IT & Chief Information OfficerMore ExecutivesKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXZoetisNYSE:ZTSGSKNYSE:GSKBristol-Myers SquibbNYSE:BMYTakeda PharmaceuticalNYSE:TAKView All CompetitorsInsiders & InstitutionsBROOKFIELD Corp ON Bought 2,366 shares on 9/26/2023Ownership: 0.027%Farther Finance Advisors LLCBought 189 shares on 9/12/2023Ownership: 0.000%Portside Wealth Group LLCBought 398 shares on 9/1/2023Ownership: 0.000%Plew Daniel P VanSold 6,197 sharesTotal: $5.22 M ($841.71/share)Alberta Investment Management CorpBought 4,121 shares on 8/24/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions REGN Stock - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price forecast for 2023? 27 equities research analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $680.00 to $1,050.00. On average, they predict the company's stock price to reach $900.92 in the next twelve months. This suggests a possible upside of 9.5% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2023? Regeneron Pharmaceuticals' stock was trading at $721.49 at the beginning of 2023. Since then, REGN stock has increased by 14.1% and is now trading at $822.96. View the best growth stocks for 2023 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our REGN earnings forecast. How can I listen to Regeneron Pharmaceuticals' earnings call? Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, November 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported $10.24 earnings per share for the quarter, topping analysts' consensus estimates of $8.48 by $1.76. The biopharmaceutical company had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.02 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 19.19% and a net margin of 33.93%. The company's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the company posted $9.77 earnings per share. Read the conference call transcript. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Biotechnology & Genome ETF (PBE), iShares Genomics Immunology and Healthcare ETF (IDNA), Subversive Mental Health ETF (SANE) and 2ndVote Life Neutral Plus ETF (LYFE). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). What is Regeneron Pharmaceuticals' stock symbol? Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN." How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Regeneron Pharmaceuticals' stock price today? One share of REGN stock can currently be purchased for approximately $822.96. How much money does Regeneron Pharmaceuticals make? Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $89.34 billion and generates $12.67 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $37.83 on an earnings per share basis. How many employees does Regeneron Pharmaceuticals have? The company employs 11,851 workers across the globe. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More How can I contact Regeneron Pharmaceuticals? Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113. This page (NASDAQ:REGN) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.